Drug Interaction Between Somatostatin and Amiodarone

Amiodarone Pharmacology and Interaction Profile

Amiodarone is metabolized by CYP3A4 and CYP2C8 to its active metabolite desethylamiodarone, and acts as an inhibitor of multiple cytochrome P450 enzymes including CYP3A4, CYP1A2, CYP2C9, and CYP2D6, according to the American Heart Association 1, 2
Amiodarone inhibits P-glycoprotein (P-gp) efflux transporter in a reversible manner, which may affect the distribution of other medications, as recommended by the American College of Cardiology 1
Amiodarone has an extremely long half-life, allowing for potential interactions months after discontinuation, as reported by the European Association for the Study of the Liver 3
Amiodarone demonstrates both irreversible (weak) inhibition by amiodarone itself and competitive (potent) inhibition by its metabolite desethylamiodarone of CYP3A4, according to the American Heart Association 1

If somatostatin is metabolized by any of the CYP enzymes inhibited by amiodarone (CYP3A4, CYP1A2, CYP2C9, CYP2D6), its levels could potentially be increased, as suggested by the American College of Clinical Pharmacology 1
If somatostatin is a substrate for P-gp, amiodarone's inhibition of this transporter could affect somatostatin's distribution, according to the International Transporter Consortium 1

The American College of Cardiology recommends that statin doses, particularly simvastatin, should be limited to 20 mg daily when co-administered with amiodarone to minimize the risk of myopathy and rhabdomyolysis 1, 4, 5
The European Association for the Study of the Liver contraindicates the use of sofosbuvir-based regimens with amiodarone due to the risk of life-threatening arrhythmias 3
The American Heart Association suggests that amiodarone may increase digoxin levels, requiring close monitoring of patients receiving both medications 6

The American College of Cardiology recommends monitoring patients closely for any unexpected effects when initiating combination therapy with somatostatin and amiodarone 1
The European Association for the Study of the Liver notes that amiodarone's long half-life means potential interactions could persist for months after discontinuation, requiring prolonged monitoring 3
The American Geriatrics Society recommends that elderly patients and those with multiple comorbidities may be at higher risk for adverse effects from potential interactions, and should be closely monitored 1, 5